Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: Following Italy in extending the lockdown but announcing no immediate easing of restrictive measures as in Spain, Macron said the tense situation in hospitals in Paris and eastern France meant there could be no let-up in the country. Since March 17, France’s 67 million people have been ordered to stay at home except to buy food, go to work, seek medical care or get some exercise on their own. The lockdown was originally scheduled to end on Tuesday. “I fully understand the effort I’m asking from you,” Macron told the nation in a televised address at the end of the lockdown’s fourth week, adding the current rules were working. “When will we be able to return to a normal life? I would love to be able to answer you. But to be frank, I have to humbly tell you we don’t have definitive answers,” he said. Schools and shops would progressively reopen on May 11, Macron said. But restaurants, hotels, cafes and cinemas would have to remain shut longer, he added. International arrivals from non-European countries will remain prohibited until further notice. Macron, whose government has faced criticism over a shortage of face masks and testing kits, said that by May 11, France would be able to test anyone presenting COVID-19 symptoms and give nonprofessional face masks to the public. Macron also said he had asked his government to present this week new financial aid for families and students in need. Acknowledging his country had not been sufficiently prepared early on to face the challenges posed by the outbreak of the new coronavirus, Macron appeared to seek a humble tone in contrast to the war-like rhetoric of his previous speeches. “Were we prepared for this crisis? On the face of it, not enough. But we coped,” he said. “This moment, let’s be honest, has revealed cracks, shortages. Like every country in the world, we have lacked gloves, hand gel, we haven’t been able to give out as many masks as we wanted to our health professionals.”  The French, long accustomed to being told their high taxes paid for the “best healthcare in the world,” have been dismayed by the rationing of critical drugs, face masks and equipment and have watched with envy the situation in neighbouring Germany. Macron’s acknowledgment of the shortcomings was broadly well-received. “It’s not every day you hear a president offer a mea culpa and dare say ‘we have no definitive answers.’ Reassuring and necessary sincerity,” analyst Maxime Sbaihi of the think tank GenerationLibre said. After a relentless increase until the first week of April, the number of patients in French hospitals’ intensive care units has started to decline, prompting health authorities to call a plateau in the epidemic. But if French hospitals are just about coping, helped by a massive effort to transfer patients by plane, helicopter or even high-speed train from hospitals in the east and Paris to the west, nursing homes have been overwhelmed. By Monday, the coronavirus had claimed 14,967 lives in France, the fourth-highest death toll in the world, with more than 98,076 confirmed cases, according to official figures. “We’ll have better days, and we’ll return to happy days,” Macron said.
[A]: Promising 'better days,' Macron extends France's lockdown until May 11.


[Q]: Seasoned explorer Robert Swan and his 23-year-old son Barney will begin their eight week, 600-mile expedition on Wednesday, hoping to show renewable energy can work in extreme conditions and prove a viable alternative to fossil fuels. “For the first time in history we will be surviving only on renewable energy. It’s never been done,” 61-year-old polar veteran Swan, the first person to walk to both the North and South poles, told Reuters. The Swans’ 5,000 daily calorie intake will come from sustainable and energy-giving foods, such as grains and almond bars, to help them overcome temperatures of -40 degrees Celsius and the obvious risks of frostbite, altitude sickness and snow blindness. Perpetual sunlight will charge the solar panels, which will power a NASA-designed ice melter to provide them with enough water for drinking and cooking. “Water is gold down in Antarctica, without it you’re going to be dying pretty quickly, as dad always reminds me,” said Barney Swan. While their aim is to complete the trek using just solar energy, under extreme weather conditions they’ll turn to an advanced biofuel made out of wood chip waste. “The fuels have been tested to minus 60 degrees Celsius...it won’t get as cold as minus 60. We may get minus 40 which is, trust me, cold enough,” the elder Swan said.
[A]: Father-son team plans Antarctic trek powered by renewable energy.


[Q]: Costs of the MRIdian on-table adaptive radiotherapy in comparison to conventional radiotherapy are not discussed. Given that it is new and more personalized than current treatment options it’s likely to be correspondingly more expensive. Certainly, more frequent MRIs would be very costly. The release provides exact information about increased survival rates in the cohorts of individuals treated with the adaptive versus the convention radiotherapy techniques. “The cohort receiving a higher dose demonstrated a near doubling of median overall survival (Kaplan-Meier estimated median overall survival of 27.8 months compared to 14.8 months).” The news release provides specific results regarding experiences of both groups with regard to toxicity from radiotherapy. We appreciate that the headline of this release starts with the words “early data” because this report deals with preliminary and retrospective research. It was not a clinical trial. Instead, results are based on retrospectively comparing treatment of two groups of patients at four institutions. Respective comparisons can’t account for a host of factors that might influence results. At the end of the news  release readers are told that on the basis of these promising results a clinical trial is being planned. With five-year survival rates of 1 to 14%, it would be hard to engage in disease mongering about pancreatic cancer. This research was sponsored by ViewRay, the company that developed the MRIdian system, and the release does a good job calling attention to this. However, according to the published study, at least one of the co-authors received honoraria from ViewRay Medical Systems. Since this was not included in the release we’re rating this criteria Not Satisfactory. This study was all about comparing alternatives, so it scores Satisfactory on that criterion. It would have helped readers if alternatives would have been described more in laymen’s terms. The news release notes that the next step is a prospective clinical trial and that tells savvy readers that this treatment strategy has a long road of testing ahead. Still, we think the release could have done a better job clarifying that this therapy is not yet ready for patients, outside of the clinical trial. A study that suggests a doubling of median survival is sure to capture the attention of patients newly diagnosed with pancreatic cancer. These patients and their families are closely aware of the glum statistics for the disease. This is a practical concern that the release should have touched on. This technology is indeed novel and unique to ViewRay, though it is becoming available in more and more cancer treatment centers. No unjustifiable language was identified in the news release.
[A]:
Early data shows nearly 2x prolonged median survival for inoperable pancreatic cancer